Pillcheck wins Arthritis Society Canada’s 2023 Award. Innovation is key to transforming arthritis care.

Pillcheck wins Arthritis Society Canada’s 2023 Award. Innovation is key to transforming arthritis care.

Veronika Litinski, MSc Medicinal Chemistry, MBA17 Aug 2023

We're thrilled to announce that the Pillcheck team was honoured to be among the four winners, selected from top innovators across Canada, at the Arthritis Society Canada’s 2023 Arthritis Ideator Awards.

Fueled by the trust and support of donors and volunteers, Arthritis Society Canada is fighting the fire of arthritis with research, advocacy, innovation, information, and support for the six million Canadians who manage this condition daily.

Pillcheck’s submission centred on using DNA-guided prescribing to ​optimize health.  An esteemed panel of judges and audience voted up Pillcheck’s easy-to-use, at-home test kit that provides a lifetime of insights to avoid medication side effects.

For more detail on the competition and the Arthritis Society’s focus on innovation, see https://arthritis.ca/about-us/what-we-do/innovation/arthritis-ideator-awards-2023.

Back to blog

About the author

Veronika Litinski

Veronika Litinski

MSc Medicinal Chemistry, MBA

Veronika is a medicinal chemist by training and first approached the health sector through cancer research at Lawrence Livermore Labs in Berkeley. Subsequently, she worked in capital markets and invested in innovative companies at GATX Capital in San Francisco. Veronika moved to Canada in 2004, where she joined the new MaRS innovation hub in Toronto. During their start-up phase, she was Director of the Venture Group, the ‘engine room’ of MaRS. Later she was Practice Lead for Health, working in one of the most complex and socially important sectors of our economy. Veronika also piloted the launch of Congniciti, a brain health company developed by Baycrest Hospital. She is currently the CEO of GeneYouIn and a leader in bringing precision medicine to health plans and individuals globally.